Chronic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Chronic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Chronic Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global chronic pain market. The report identifies the key trends shaping and driving the global chronic pain market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global chronic pain sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global chronic pain therapeutics market was valued at $18 billion in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 4.7% over the next seven years, to reach $24.9 billion by 2017. This slow growth is primarily attributed to low treatment seeking behavior and disease awareness and the use of generic drugs.

Scope

The report provides information on the key drivers and challenges of the chronic pain market. Its scope includes -

• Annualized global chronic pain market revenues data from 2005 to 2010, forecast for seven years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as NGF binders, TRPV antagonists, calcium channel blockers, non-peptide neurotoxins, alpha adrenergic receptors, p38 kinase inhibitors, fatty acid amide hydrolase inhibitors, alpha-2 delta ligands, amino-amide type local anesthetics, interleukin-1β blockers, N-methyl-D-aspartate receptors (NMDA), glial cell regulators, chemokine antagonists and so on.
• Analysis of the current and future competition in the global chronic pain market. Key market players covered are Pfizer Inc., Grunenthal GmbH, Cephalon Inc., SantoSolve AS, Transdel Pharmaceuticals, WEX Pharmaceuticals, Avanir Pharmaceuticals, Elite Pharmaceuticals, Horizon Therapeutics, King Pharmaceuticals, Insys Therapeutics and Endo Pharmaceuticals.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the chronic pain therapeutics market.
• Analysis of key recent licensing and partnership agreements in chronic pain therapeutics market

Reasons to buy
The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global chronic pain market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global chronic pain market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global chronic pain market landscape? - Identify, understand and capitalize

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 CHRONIC PAIN THERAPEUTICS - INTRODUCTION

2.1 Disease Overview
  2.1.1 Types of Chronic Pain
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.4 Signs and Symptoms
2.5 Diagnosis
  2.5.1 Commonly Used Pain Scales
  2.5.2 Commonly Used Diagnosis Tests
2.6 Treatment and Management Options
2.7 GlobalData Pipeline Report Guidance

3 CHRONIC PAIN THERAPEUTICS - MARKET CHARACTERIZATION

3.1 Chronic Pain Therapeutics Market Size (2005–2010) – Global
3.2 Chronic Pain Therapeutics Market Forecast (2010–2017) – Global
3.3 Chronic Pain Therapeutics Market Size (2005–2010) – The US
3.4 Chronic Pain Therapeutics Market Forecast (2010–2017) – The US
3.5 Chronic Pain Therapeutics Market Size (2005–2010) – France
3.6 Chronic Pain Therapeutics Market Forecast (2010–2017) – France
3.7 Chronic Pain Therapeutics Market Size (2005–2010) – Germany
3.8 Chronic Pain Therapeutics Market Forecast (2010–2017) – Germany
3.9 Chronic Pain Therapeutics Market Size (2005–2010) – Italy
3.10 Chronic Pain Therapeutics Market Forecast (2010–2017) – Italy
3.11 Chronic Pain Therapeutics Market Size (2005–2010) – Spain
3.12 Chronic Pain Therapeutics Market Forecast (2010–2017) – Spain
3.13 Chronic Pain Therapeutics Market Size (2005–2010) – The UK
3.14 Chronic Pain Therapeutics Market Forecast (2010–2017) – The UK
3.15 Chronic Pain Therapeutics Market Size (2005–2010) – Japan
3.16 Chronic Pain Therapeutics Market Forecast (2010–2017) – Japan
3.17 Drivers and Barriers for the Chronic Pain Therapeutics Market
  3.17.1 Drivers for the Chronic Pain Therapeutics Market
  3.17.2 Barriers for the Chronic Pain Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway

4 CHRONIC PAIN THERAPEUTICS- COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Chronic Pain Therapeutics Market
  4.3.1 Celebrex (celecoxib)
  4.3.2 Voltaren Gel (diclofenac sodium)
  4.3.3 Cymbalta (duloxetine hydrochloride)
  4.3.4 Lyrica (pregabalin)
  4.3.5 Morphine
4.4 Key Takeaway

5 CHRONIC PAIN THERAPEUTICS - PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Chronic Pain Therapeutics Pipeline – Pipeline by Phases of Development
  5.3.1 Chronic Pain Therapeutics – Regulatory Filed Products
  5.3.2 Chronic Pain Therapeutics – Phase III Pipeline
  5.3.3 Chronic Pain Therapeutics – Phase II Pipeline
  5.3.4 Chronic Pain Therapeutics – Phase I Pipeline
  5.3.5 Chronic Pain Market – Discovery and Pre-Clinical Pipeline
  5.3.6 Technology Trends Analytic Framework
5.4 Chronic Pain Therapeutics Market – Pipeline by Mechanism of Action
5.5 Chronic Pain Therapeutics – Promising Drugs Under Clinical Development
5.6 Molecule Profile for Promising Drugs Under Clinical Development
  5.6.1 AVP-923 (Zenvia)
  5.6.2 Tetrodotoxin for cancer-related pain (Tectin)
  5.6.3 2PX (topical strontium chloride hexahydrate)
5.7 Key Takeaway

6 CHRONIC PAIN THERAPEUTICS - CLINICAL TRIALS MAPPING

6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Chronic Pain Therapeutics Clinical Trials

7 STRATEGIC ASSESSMENT

7.1 Key Events Impacting the Future Market
7.2 Chronic Pain Therapeutics - Implications for Future Market Competition

8 CHRONIC PAIN THERAPEUTICS - FUTURE PLAYERS

8.1 Introduction
8.2 Company Profiles
  8.2.1 Pfizer Inc.
  8.2.2 Grunenthal GmbH
  8.2.3 Transdel Pharmaceuticals, Inc.
  8.2.4 WEX Pharmaceuticals
  8.2.5 Avanir Pharmaceuticals
  8.2.6 Cephalon, Inc.
  8.2.7 Elite Pharmaceuticals
  8.2.8 Endo Pharmaceuticals
  8.2.9 Depomed Inc.
  8.2.10 Other Companies in the Chronic Pain Therapeutics Market

9 CHRONIC PAIN THERAPEUTICS - LICENSING AND PARTNERSHIP DEALS

10 CHRONIC PAIN THERAPEUTICS - APPENDIX

10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
  10.3.1 Coverage
  10.3.2 Secondary Research
  10.3.3 Forecasting
  10.3.4 Primary Research
  10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

LIST OF TABLES

Table 1: Differentiation of Chronic Pain from Acute Pain
Table 2: Chronic Pain Therapeutics Market, Global, Revenue ($bn), 2005–2010
Table 3: Chronic Pain Therapeutics Market, Global, Forecast ($bn), 2010–2017
Table 4: Chronic Pain Therapeutics Market, The US, Revenue ($bn), 2005–2010
Table 5: Chronic Pain Therapeutics Market, The US, Forecasts ($bn), 2010–2017
Table 6: Chronic Pain Therapeutics Market, France, Revenue ($m), 2005–2010
Table 7: Chronic Pain Therapeutics Market, France, Forecasts ($m), 2010–2017
Table 8: Chronic Pain Therapeutics Market, Germany, Revenue ($bn), 2005–2010
Table 9: Chronic Pain Therapeutics Market, Germany, Forecasts ($bn), 2010–2017
Table 10: Chronic Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 11: Chronic Pain Therapeutics Market, Italy, Forecasts ($m), 2010–2017
Table 12: Chronic Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 13: Chronic Pain Therapeutics Market, Spain, Forecasts ($m), 2010–2017
Table 14: Chronic Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010
Table 15: Chronic Pain Therapeutics Market, The UK, Forecasts ($m), 2010–2017
Table 16: Chronic Pain Therapeutics Market, Japan, Revenue ($bn), 2005–2010
Table 17: Chronic Pain Therapeutics Market, Japan, Forecasts ($bn), 2010–2017
Table 18: Clinical Trials of Cymbalta
Table 19: Clinical Trials of Lyrica
Table 20: Chronic Pain Therapeutics, Regulatory Filed Products, 2011
Table 21: Chronic Pain Therapeutics, Phase III Pipeline, 2011
Table 22: Chronic Pain Therapeutics, Phase II Pipeline, 2011
Table 23: Chronic Pain Therapeutics, Phase I Pipeline, 2011
Table 24: Chronic Pain Therapeutics, Discovery and Pre-Clinical Pipeline, 2011
Table 25: Chronic Pain Therapeutics – Most Promising Drugs Under Clinical Development, 2011
Table 26: Chronic Pain Therapeutics, Clinical Trials by Country, 2011
Table 27: Chronic Pain Therapeutics - Clinical Trials by Phase, 2011
Table 28: Chronic Pain Therapeutics, Clinical Trials by Status (%), 2011
Table 29: Chronic Pain Therapeutics, Prominent Sponsors, 2011
Table 30: Chronic Pain Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 31: Pfizer Inc., Pain Management, Pipeline, 2011
Table 32: Pfizer, Inc., Deals, 2010–2011
Table 33: Grunenthal GmbH, Pain Management, Pipeline, 2011
Table 34: Grunenthal GmbH, Deals, 2010-11
Table 35: Transdel Pharmaceuticals – Pain Management, Pipeline, 2011
Table 36: Transdel Pharmaceuticals, Inc. – Deals, 2010-11
Table 37: WEX Pharmaceuticals, Pain Management Pipeline, 2011
Table 38: WEX Pharmaceuticals Inc., Deals , 2010-11
Table 39: Avanir Pharmaceuticals – Pain Management, Pipeline, 2011
Table 40: Avanir Pharmaceuticals – Deals, 2009-2010
Table 41: Cephalon, Inc., Pain Management Pipeline, 2011
Table 42: Transdel Pharmaceuticals, Inc., Deals, 2010–2011
Table 43: Elite Pharmaceuticals, Pain Management, Pipeline, 2011
Table 44: Elite Pharmaceuticals, Deals, 2010–2011
Table 45: Endo Pharmaceuticals, Pain Management, Pipeline, 2011
Table 46: Endo Pharmaceuticals, Deals, 2009-11
Table 47: Depomed Inc, Pain Management, Pipeline, 2011
Table 48: Depomed, Inc, Deals, 2009–2011
Table 49: Chronic Pain Therapeutics Market, Future Players
Table 50: Chronic Pain Therapeutics, Global, Deals, 2009-2011

LIST OF FIGURES

Figure 1: Classification of Chronic Pain and Representative Indications
Figure 2: Pathophysiology of Nociceptive Pain
Figure 3: Pathophysiology of Neuropathic Pain
Figure 4: Pain Measurement Scale – Numeric Rating Scale
Figure 5: Pain Measurement Scale – Visual Analog Scale
Figure 6: Pain Measurement Scale – Faces Rating Scale
Figure 7: Chronic Pain Relief Treatment Chart, 2011
Figure 8: Chronic Pain Therapeutics Market, Global, Revenue ($bn), 2005–2010
Figure 9: Chronic Pain Therapeutics Market, Global, Forecast ($bn), 2010–2017
Figure 10: Chronic Pain Therapeutics Market, The US, Revenue ($bn), 2005–2010
Figure 11: Chronic Pain Therapeutics Market, The US, Forecast ($bn), 2010–2017
Figure 12: Chronic Pain Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 13: Chronic Pain Therapeutics Market, France, Forecast ($m), 2010–2017
Figure 14: Chronic Pain Therapeutics Market, Germany, Revenue ($bn), 2005–2010
Figure 15: Chronic Pain Therapeutics Market, Germany, Forecast ($bn), 2010–2017
Figure 16: Chronic Pain Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 17: Chronic Pain Therapeutics Market, Italy, Forecast ($m), 2010–2017
Figure 18: Chronic Pain Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 19: Chronic Pain Therapeutics Market, Spain, Forecast ($m), 2010–2017
Figure 20: Chronic Pain Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 21: Chronic Pain Therapeutics Market, The UK, Forecast ($m), 2010–2017
Figure 22: Chronic Pain Therapeutics Market, Japan, Revenue ($bn), 2005–2010
Figure 23: Chronic Pain Therapeutics Market, Japan, Forecast ($bn), 2010–2017
Figure 24: Opportunity and Unmet Need in the Chronic Pain Therapeutics Market, 2010
Figure 25: Chronic Pain Therapeutics, Strategic Competitor Assessment, 2010
Figure 26: Chronic Pain Therapeutics – Pipeline by Phase of Development, 2011
Figure 27: Chronic Pain Therapeutics, Technology Trends Analytics Framework, 2011
Figure 28: Chronic Pain Therapeutics, Technology Trends Analytics Framework, Description, 2011
Figure 29: Chronic Pain Therapeutics, Pipeline by Mechanism of Action (%), 2011
Figure 30: Chronic Pain Therapeutics, Clinical Trials by Country, 2011
Figure 31: Chronic Pain Therapeutics, Clinical Trials by Phase (%), 2011
Figure 32: Chronic Pain Therapeutics, Clinical Trials by Status (%), 2011
Figure 33: Chronic Pain Therapeutics, Overall Sponsors (%), 2011
Figure 34: Chronic Pain Therapeutics, Prominent Sponsors (%), 2011
Figure 35: Chronic Pain Therapeutics, Top Companies Participating in Clinical Trials, 2011
Figure 36: Chronic Pain Therapeutics Market, Drivers and Restraints 2011
Figure 37: Implications for Future Market Competition in the Chronic Pain Market, 2011
Figure 38: Chronic Pain Therapeutics Market, Pipeline by Company, 2011
Figure 39: GlobalData Market Forecasting Model

COMPANIES MENTIONED

Pfizer Inc.
Grunenthal GmbH
Transdel Pharmaceuticals, Inc.
WEX Pharmaceuticals
Avanir Pharmaceuticals
Cephalon, Inc.
Elite Pharmaceuticals
Endo Pharmaceuticals
Depomed Inc. Skip to top